MedTrace Logo

Efficacy of Liposomal Bupivacaine Post Septorhinoplasty

NCT05964868 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-03

No results posted yet for this study

Summary

The objective of this study is to determine if there is a difference in post-operative pain after septorhinoplasty when long-acting liposomal bupivacaine is used for local anesthesia compared to other standard local anesthetic regimens.

Conditions

  • Rhinoplasty
  • Pain Management

Interventions

DRUG

Liposomal Bupivacaine

Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.

DRUG

0.25% bupivacaine with 1:200,000 epinephrine

Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.

OTHER

Placebo - Saline solution

This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.

Sponsors & Collaborators

  • Jessyka Lighthall

    lead OTHER

Principal Investigators

  • Jessyka Lighthall, MD · Penn State Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-05
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05964868 on ClinicalTrials.gov